<< Read Full Article
<< Read Full Article
Health care stocks started the week mixed amid a smattering of earnings, trial data and other news.
AstraZeneca(AZN Quote) said Monday that its heart drug Brilinta worked better than Bristol-Myers Squibb's(BMY Quote) and Sanofi-Aventis'(SNY Quote) blockbuster blood-thinner Plavix in a study.
According to U.K.-based AstraZeneca, the drug was more effective at preventing serious cardiac events such as myocardial infarction, stroke and cardiovascular death than clopidogrel, or Plavix, in a stage III trial. The company said it plans to submit the drug to regulatory authorities in the fourth quarter of 2009.
AstraZeneca shares were up 5.6% to $38.15. Bristol shares were down 0.5% to $20.29, and Sanofi-Aventis slipped 1% to $29.86. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,410.21 | 1,113.35 | 2,235.64 | 36.82 |
Oil *
72.70
|
|
UP
81.32
|
UP
10.88
|
UP
23.95
|
UP
1.36
|
10 Yr
3.68%
SPDR Gold
107.12
|
|
+0.79%
|
+0.99%
|
+1.08%
|
+3.84%
|
Data delayed 20 minutes |
Connect with TheStreet